… We aimed to evaluate efficacy and safety of combination treatment in immunocompromised
… and safety of triple combination therapy in severely immunocompromised patients with SARS…

… controlled trials (RCT) of combined therapies in IC COVID-19 patients, we review here the
in vitro … supporting combined therapy with different antiviral MOAs for IC COVID-19 patients. …

… of combination treatment … Triple combination therapy with two antivirals and monoclonal
antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients …

… clinical trials involving triple combination therapy with dual nucleoside reverse transcriptase
… triple); a non-nucleoside reverse transcriptase inhibitor (NNRTI triple); or a third NRTI (triple …

… This case series included immunocompromised patients who received antiviral and/or
antibody combination therapies for persistently symptomatic SARS-CoV-2 infections. Patients …

… treatment of … combination treatment with two antivirals targeting different viral proteins,
together with the mAb sotrovimab in the early phase of COVID-19 in immunocompromised patients …

… therapy naive HIV-positive individuals aged 18 years and older in British Columbia who
started triple-combination therapy between August 1996 and December 1999. Therapy use was …

… longer treatment or additional courses of antivirals in patients … use of combined therapy in
immunocompromised patients, … ], and death [3, 4] remains high. Moreover, longer courses of …

… safety of combination therapy vs. monotherapy in high-risk immunocompromised patients
with mild-… the subgroups of immunosuppressed patients who could benefit from this treatment. …

… We aimed to evaluate efficacy and safety of combination treatment in immunocompromised
COVID-19 patients.We included all immunocompromised patients with prolonged/relapsed …